LeMaitre Vascular, Inc. (LMAT)

LeMaitre Vascular's stock has been impacted by several events in the past six months. The company reported strong Q4 2025 results, leading to a stock surge. The Board of Directors approved a dividend increase and a share repurchase program. Several analysts raised their price targets for LMAT, resulting in a consensus rating of "Moderate Buy". There has been significant insider selling. LeMaitre Vascular participated in several investor conferences.

Demand for LeMaitre Vascular's products and services is generally characterized by consistent demand for vascular interventions globally. The company benefits from expanding market opportunities driven by new products, regulatory approvals, and demographic trends. The nature of medical devices for treating peripheral vascular disease suggests a relatively stable demand profile, as these are often critical medical procedures not typically subject to significant seasonal variations.

LeMaitre Vascular, Inc. is a specialty medical device company focused on developing, manufacturing, and marketing products for peripheral vascular disease treatment. The company provides devices, implants, and human tissue cryopreservation services used by vascular surgeons, with a product portfolio addressing arterial reconstruction, endovascular repair, and vascular access. Key products include biologic grafts, patches, allografts, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, carotid shunts, biosynthetic vascular grafts, phlebectomy systems, vascular grafts, radiopaque tape, valvulotomes, and closure systems. The company markets its products through a direct sales force and distributors.

LeMaitre Vascular has a global presence, selling directly to hospitals in 25 countries and through distributors in over 70 countries across North America, Europe, the Middle East, Africa, and the Asia Pacific region. The company's headquarters are located in Burlington, Massachusetts, U.S. While it has a broad international reach, the majority of its revenue is generated in the United States.

LeMaitre Vascular has built a strong brand reputation, characterized by a durable competitive advantage through niche market dominance, regulatory barriers, and entrenched relationships with vascular surgeons. The company is recognized for its commitment to innovation. Annual reports from LeMaitre Vascular, Inc. have a high usefulness score, indicating a positive perception of its corporate communications and performance.

LeMaitre Vascular, Inc. is primarily owned by institutional investors, who hold the vast majority of the company's stock. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and others. Founders and insiders also retain meaningful positions, with insider ownership accounting for nearly 10%. George W. LeMaitre, the Chairman and CEO, is a significant individual shareholder.